DelveInsight has launched a new report on Autosomal Dominant Polycystic Kidney Disease – Epidemiology Forecast to 2030
DelveInsight’s ‘Autosomal Dominant Polycystic Kidney Disease – Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Autosomal Dominant Polycystic Kidney Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Some of the key facts of the Report:
“According to DelveInsight’s analysis, ADPKD is the most common in adults and is most frequent in higher age groups and 50% of ADPKD may progress to ESRD by 60 years of age.”
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a genetic disorder which causes pathological cystic changes to the kidney and is characterized by numerous renal and systemic manifestations. Renal manifestations are produced by the progressive and continuous enlargement and proliferation of fluid-filled cysts, leading to enlargement of the kidney up to five times the normal volume in the years prior to the development of kidney failure.
ADPKD may led to development of end-stage renal disease (ESRD) and is the fourth most common renal disease requiring renal replacement therapy (RRP). The most common extrarenal manifestation is polycystic liver disease (PLD), which is more common in women than in men.
Genetic mutation plays a major role in the pathogenesis of ADPKD, mainly mutations in the PKD1, PKD2 genes leads to cyst formation and its progressive growth.
As per the WHO classification, there are two types of PKD: autosomal dominant (ADPKD) and autosomal recessive (ARPKD). The gene mutations in the PKHD1 gene cause ARPKD, occurring mostly in children.
“According to DelveInsight, DelveInsight’s Analysis, it can be observed that diagnosis of ADPKD is high in the 7MM.”
Request for Sample Pages https://www.delveinsight.com/sample-request/autosomal-dominant-polycystic-kidney-disease-epidemiology-forecast
Scope of the Report
KOL- Views
We interview, KOLs and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
Key Questions Answered
Reasons to buy
Key Assessments
Related Reports:
Autosomal Dominant Polycystic Kidney Disease – Pipeline Insights, 2020
The Autosomal Dominant Polycystic Kidney Disease report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Autosomal Dominant Polycystic Kidney Disease across the complete product development cycle, including all clinical and nonclinical stages.
Autosomal Dominant Polycystic Kidney Disease- Market Insight, Epidemiology and Market Forecast -2030
The Autosomal Dominant Polycystic Kidney Disease market report provides current treatment practices, emerging drugs, Autosomal Dominant Polycystic Kidney Disease market share of the individual therapies, current and forecasted Autosomal Dominant Polycystic Kidney Disease market Size from 2017 to 2030 segmented by seven major markets.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NEVADA 89107Country: United StatesWebsite: https://www.delveinsight.com/